Sensei Biotherapeutics, Inc. reported earnings results for the third quarter ended September 30, 2023. For the third quarter, the company reported net loss was USD 7.12 million compared to USD 13.42 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.44 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 USD | -45.52% |
|
-48.37% | +14.16% |
May. 14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
May. 09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.16% | 36.37M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023